Last reviewed · How we verify
SPARC0912
SPARC0912 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to modulate gene expression and induce anti-tumor effects.
SPARC0912 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to modulate gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).
At a glance
| Generic name | SPARC0912 |
|---|---|
| Sponsor | Sun Pharma Advanced Research Company Limited |
| Drug class | Histone deacetylase (HDAC) inhibitor |
| Target | Histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HDAC enzymes, SPARC0912 increases histone acetylation, leading to chromatin remodeling and altered transcription of genes involved in cell cycle arrest, differentiation, and apoptosis. This mechanism is particularly relevant in hematologic malignancies where HDAC inhibition can restore tumor suppressor gene expression and trigger cancer cell death.
Approved indications
- Peripheral T-cell lymphoma (PTCL)
- Cutaneous T-cell lymphoma (CTCL)
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPARC0912 CI brief — competitive landscape report
- SPARC0912 updates RSS · CI watch RSS
- Sun Pharma Advanced Research Company Limited portfolio CI